Having already purchased $1.8 billion worth of stock so far this year and having exhausted its existing $2.5 billion share repurchase program, biopharmaceutical Celgene announced this morning that its board of directors has authorized a new $3 billion buyback program.

Celgene said the purchases may be made in the open market or through privately negotiated transactions. Over the last four years, the biopharmaceutical has bought back approximately $6.5 billion of its stock.

Headquartered in Summit, N.J., Celgene is engaged in the discovery, development, and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. It generated $5.7 billion in revenues over the last 12-month period ending March 31.


CELG Stock Buybacks Chart

CELG Stock Buybacks data by YCharts.

The article Celgene Adds $3 Billion to Buyback Program originally appeared on Fool.com.

Fool contributor Rich Duprey has no position in any stocks mentioned. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Investing in Startups

The lucrative and risky world of startups.

View Course »

Portfolio Basics

What are stocks? Learn how to start investing.

View Course »

Add a Comment

*0 / 3000 Character Maximum